Mangalam drugs & organics Limited has submitted its quarterly compliance certificate under SEBI Depositories Regulations to stock exchanges. The pharmaceutical company filed the mandatory certificate for the quarter ended March 31, 2026, demonstrating adherence to regulatory requirements for securities handling and dematerialisation processes.

Regulatory Compliance Submission

The company submitted the compliance certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 on April 06, 2026. The certificate covers the period from January 01, 2026 to March 31, 2026, ensuring transparency in securities dematerialisation operations.

Certificate Confirmation Details

MUFG Intime India Private Limited, serving as the company's Registrar and Share Transfer Agent, issued the compliance certificate on April 3, 2026. The certificate confirms that securities received from depository participants for dematerialisation during the quarter were properly processed and confirmed to the depositories within prescribed timelines.

The registrar confirmed that all security certificates received for dematerialisation were appropriately verified, mutilated, and cancelled after due verification by depository participants. Additionally, the names of depositories were substituted in the register of members as registered owners following established procedures.

Stock Exchange Communication

The compliance certificate was formally communicated to both major Indian stock exchanges where the company's securities are listed. Managing Director Govardhan M. Dhoot signed the submission letter, requesting the exchanges to take the certificate on record as part of ongoing regulatory compliance.

The submission represents the company's commitment to maintaining regulatory compliance and transparency in securities operations, ensuring proper handling of investor securities through authorized depository participants and maintaining accurate records of ownership transfers.

Mangalam drugs & organics Limited has successfully concluded its board meeting on March 26, 2026, officially approving significant changes in its Company Secretary position. The board meeting, held at the company's registered office in Mumbai, addressed the planned transition in key managerial personnel as previously announced.

Board Meeting Outcome

The board meeting commenced at 12:00 PM and concluded at 12:40 PM on Thursday, March 26, 2026. The meeting was conducted under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring compliance with regulatory requirements for material disclosures.

Personnel Changes Approved

The board formally approved two critical agenda items related to the Company Secretary transition:

Ms. Anuradha Pandey's resignation from the position of Company Secretary & Compliance Officer was officially accepted by the board. Her resignation letter, dated January 2, 2026, cited her decision to pursue opportunities outside the company. Her last day of service will be March 29, 2026.

New Company Secretary Profile

The board approved the appointment of Ms. Shweta Patel as the new Company Secretary & Compliance Officer, effective April 1, 2026. Ms. Patel brings relevant qualifications and experience to the role:

Ms. Patel is an Associate Member of the Institute of Company Secretaries of India and has three years of experience handling corporate compliances with statutory and regulatory requirements for listed companies, along with public and private company groups.

Regulatory Compliance

The company has communicated the board meeting outcomes to both BSE Limited and National Stock Exchange of India Limited as required under listing regulations. The notification was signed by Chairman & Managing Director Govardhan M. Dhoot, ensuring proper disclosure of material changes in key managerial positions.